(19)
(11) EP 4 568 674 A1

(12)

(43) Date of publication:
18.06.2025 Bulletin 2025/25

(21) Application number: 23757233.4

(22) Date of filing: 11.08.2023
(51) International Patent Classification (IPC): 
A61K 31/517(2006.01)
A61K 31/497(2006.01)
A61K 39/39(2006.01)
A61P 35/00(2006.01)
 A61K 31/436(2006.01)
A61K 31/519(2006.01)
A61K 45/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/517; A61K 31/519; A61K 31/497; A61K 31/436; A61K 45/06; A61P 35/00; A61K 39/39
 
C-Sets:
  1. A61K 39/39, A61K 2300/00;
  2. A61K 31/517, A61K 2300/00;
  3. A61K 31/519, A61K 2300/00;
  4. A61K 31/497, A61K 2300/00;
  5. A61K 31/436, A61K 2300/00;
(86) International application number:
PCT/EP2023/072324
(87) International publication number:
WO 2024/033537 (15.02.2024 Gazette 2024/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 12.08.2022 EP 22190139

(71) Applicant: Astellas Pharma Inc.
Tokyo, 103-8411 (JP)

(72) Inventors:
  • NAGASHIMA, Takeyuki
    Tokyo, 103--8411 (JP)
  • TASAKI, Mamoru
    Tokyo, 103--8411 (JP)

(74) Representative: Potter Clarkson 
Chapel Quarter Mount Street
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)

   


(54) COMBINATION OF ANTICANCER AGENTS COMPRISING A BIFUNCTIONAL COMPOUND WITH G12D MUTANT KRAS INHIBITORY ACTIVITY